Chronic brain infusion of topotecan for recurrent glioma
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment called topotecan that is delivered directly into the brain through a small tube (convection-enhanced delivery). It is for people whose IDH-mutant glioma has come back despite standard treatment. The goal is to see if this approach can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain tumor called recurrent IDH-mutant malignant glioma (grade 3 or 4) that has grown back after standard treatment.
- Your tumor must be a single, accessible spot in the brain that is smaller than about the size of a golf ball (less than 32 cc) and not pressing on important areas.
- You must be well enough to have a Karnofsky score of 70 or higher (able to care for yourself but not do full normal activities).
- You must be at least 18 years old and willing to undergo brain surgery to place the delivery tube.
- Your bone marrow, liver, and kidney function must be within safe limits (checked by blood tests).
- If you are of childbearing age, you must use birth control during and for some time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
Hear when a new Brain Tumor, Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.